Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Operating Expenses: 2023-2025

Historic Operating Expenses for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to $33.8 million.

  • Inhibrx Biosciences' Operating Expenses fell 27.75% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.4 million, marking a year-over-year decrease of 58.17%. This contributed to the annual value of $331.6 million for FY2024, which is 50.05% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Operating Expenses is $33.8 million, which was up 17.86% from $28.7 million recorded in Q2 2025.
  • Inhibrx Biosciences' Operating Expenses' 5-year high stood at $161.0 million during Q2 2024, with a 5-year trough of $28.7 million in Q2 2025.
  • Moreover, its 3-year median value for Operating Expenses was $46.4 million (2023), whereas its average is $61.7 million.
  • Per our database at Business Quant, Inhibrx Biosciences' Operating Expenses spiked by 267.72% in 2024 and then slumped by 82.18% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Operating Expenses stood at $89.9 million in 2023, then plummeted by 44.37% to $50.0 million in 2024, then dropped by 27.75% to $33.8 million in 2025.
  • Its last three reported values are $33.8 million in Q3 2025, $28.7 million for Q2 2025, and $42.9 million during Q1 2025.